INTELLIGENT REFRIGERATED AUTOMATIC STORAGE SYSTEM

智能冷藏自动化仓储系统

• 批准号: 3509433
• 负责人: BYRON L NIELSON
• 金额: $ 21.99万
• 依托单位: AUTOMATED CONTROL SYSTEMS, INC.
• 依托单位国家: 美国
• 财政年份: 1992
• 资助国家: 美国
• 起止时间: 1992-09-30 至 1994-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3509433
• 关键词: DVD /CD ROM; artificial intelligence; biomedical automation; biomedical equipment development; cold temperature; computer data analysis; computer human interaction; computer program /software; computer system design /evaluation; cryopreservation; information systems; laboratory accident /infection; occupational health /safety; online computer; personal computers; robotics; safety equipment

An advanced Phase II prototype for a computer-controlled Intelligent Refrigerated Automatic Storage System (IRASS) for medical laboratories will be developed. The system will build on the features of the Phase I project: a database to track storage/retrieval/discard of specimens, bar code reading for specimen identification, robotic hardware for movement of specimens. Additionally extensive safety engineering, an advanced user- friendly interface incorporating text windowing and advanced input devices, a smart loading platform, optimization of motion control, hooks for communications with laboratory computers, specimen disposition logic and fault tolerance will be provided. At the end of the Phase II trial, an extensive field evaluation will take place in an actual clinical laboratory setting. This system has the potential of reducing labor costs required for the storage/retrieval of specimens, increasing test reliability by improved specimen identification, and decreasing the risk of infection for laboratory workers. Phase II will include extensive evaluations of software and hardware necessary before market release of a sophisticated IRASS, GRANT-R01MH48759 This is a proposal for a random assignment, double-blind, placebo- controlled clinical trial of carbamazepine in 66 probable and possible AD outpatients with clinically significant behavioral disorders. The duration of study is six weeks with a 10 to 7 day screening period (run-in). Subjects will be assessed for efficacy at biweekly intervals using validated instruments by raters blind to treatment condition. A clinical monitor who is open to medication status will evaluate subjects weekly to enhance safety. Subjects originally assigned to placebo will be offered an open six week trial of medication under similar study conditions. After the six week trial, there will be an open, uncontrolled, continuation phase of 24 week's duration to assess safety, drug autometabolism, and continuing efficacy. Patients will be seen at monthly intervals for follow-up. The objective of this study is to compare carbamazepine (400 to 300 mg/d) to a placebo control in terms of efficacy and side effects in treating agitated AD patients. Measures of efficacy include the Brief Psychiatric Rating Scale (BPRS), Clinical Global Improvement Scale (CGI), Hamilton Rating Scale for Depression, Relatives' Assessment of Global Symptomatology-Elderly (RAGS-E), the Physical Self-Maintenance Scale and Instrumental Activities of Daily Living (PSMS/IADL). The primary criterion for clinical response is a > 30% improvement on the agitation factor of the BPRS, and a 'much improved' rating on the CGI. A minimum effect size for carbamazepine is defined (r=0.18). A secondary objective is to replicate a prior observation that platelet 3H- imipramine binding B max is decreased, and MAO activity is relatively decreased in Alzheimer's patients with symptomatic behaviors compared to Alzheimer's disease patients without symptomatic behaviors.

计算机控制智能系统的先进二期原型 用于医学实验室的自动冷藏存储系统（IRASS）将 得到开发。 该系统将建立在第一阶段的功能之上 项目：跟踪样本存储/检索/丢弃的数据库，酒吧 用于样本识别的代码读取、用于移动的机器人硬件 标本。 此外，广泛的安全工程、先进的用户 友好的界面结合了文本窗口和先进的输入设备， 智能装载平台，优化运动控制，挂钩 与实验室计算机、样本处理逻辑和 将提供容错功能。 在第二阶段试验结束时， 广泛的现场评估将在实际的临床实验室进行 环境。 该系统有可能降低所需的劳动力成本 用于样本的存储/检索，通过以下方式提高测试可靠性 改进标本鉴定，降低感染风险 实验室工作人员。 第二阶段将包括广泛的评估 在向市场发布复杂的产品之前必需的软件和硬件 伊拉斯， 格兰特-R01MH48759 这是一项随机分配、双盲、安慰剂的提案 卡马西平治疗 66 例可能和可能的 AD 的对照临床试验 患有临床显着行为障碍的门诊患者。 持续时间 研究为期六周，其中有 10 至 7 天的筛选期（磨合期）。 将每两周一次评估受试者的疗效 由不了解治疗条件的评估者验证仪器。 临床一 监测谁对药物状态持开放态度将每周评估受试者 增强安全性。 最初分配给安慰剂的受试者将被提供 在类似的研究条件下开展为期六周的药物试验。 后 六周的试验，将有一个开放的、不受控制的持续阶段 为期 24 周的持续时间来评估安全性、药物自动代谢和持续 功效。 患者将每月进行一次随访以进行随访。 本研究的目的是比较卡马西平（400 至 300 毫克/天） 就治疗的功效和副作用而言，与安慰剂对照相比 烦躁的 AD 患者。 功效测量包括简短的精神病学 评定量表 (BPRS)、临床整体改善量表 (CGI)、汉密尔顿 抑郁症评定量表、亲属对全球的评估 老年人症状学 (RAGS-E)、身体自我维护量表和 日常生活工具性活动（PSMS/IADL）。 主要标准 临床反应是激动因素改善 > 30% BPRS 以及 CGI 的评级“大大提高”。 最小效应量为 卡马西平被定义（r=0.18）。 次要目标是复制先前的观察结果，即血小板 3H- 丙咪嗪结合B max 降低，MAO活性相对降低 与阿尔茨海默病患者相比，有症状行为的患者的行为有所减少 阿尔茨海默病患者无症状行为。